• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec10
Mizuho Securities Analyst Reiterates Buy Rating for Nurix Therapeutics
13:38
Dec8
Stifel Nicolaus Maintains Buy Rating on Nurix Therapeutics
13:32
Nurix Therapeutics Unveils Phase 1 Trial Data of Bexobrutideg at ASH Annual Meeting
13:07
Nov7
Oppenheimer Reiterates Buy Rating on Nurix Therapeutics
19:56
Nov4
Gil Blum gives Nurix Therapeutics' bexodeg a buy rating
10:16
Oct23
Nurix Therapeutics Maintained at Hold Rating
08:47

Schedules & Filings

Schedules
Filings
Oct9
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 7.894 M, Net Income -86.42 M, EPS -1.0268

Jul9
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 44.06 M, Net Income -43.46 M, EPS -0.5181

Apr8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 18.45 M, Net Income -56.35 M, EPS -0.6743

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More